Registry based analysis of cost-of-illness study among stage C heart failure patients at Hospital Queen Elizabeth II, Sabah, Malaysia

Shafie, Asrul Akmal; Tan, Yui Ping; Liau, Siow Yen; Yang, Su Lan; Liew, Houng Bang; Chaiyakunapruk, Nathorn

doi:10.1016/j.hlpt.2019.01.002

Cited by 7 publications

(19 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These components showed the same outcome from another local study (10), as well as a study from another country (51). On the other hand, the mean hospitalisation cost in the current study was much lower than another local COI study (USD 1,473 vs. USD 5,454), although both studies had similar lengths of hospital stays (10). However, when comparing the median costs, which is more preferable due to exclusion of possible outliers, both studies reported comparable inpatient costs.…”

Section: Resource Utilisation By Healthcare Componentssupporting

confidence: 75%

“…Analysis of the individual components of HF care cost revealed that interventional procedures were the main cost driver of HF. These components showed the same outcome from another local study (10), as well as a study from another country (51). On the other hand, the mean hospitalisation cost in the current study was much lower than another local COI study (USD 1,473 vs. USD 5,454), although both studies had similar lengths of hospital stays (10).…”

Section: Resource Utilisation By Healthcare Componentssupporting

confidence: 73%

“…On the other hand, a high proportion of HF patients in the study were male patients. This finding was supported by a COI study done by Shafie et al, which had 85.9% of male patients (10). Additionally, the Malaysia Heart Failure Registry (MyHF) consisting of a total of 2673 patients reported that about two-thirds of the HF patients were males, and 75% of the patients with HFrEF were males (24).…”

Section: Demographic Of Study Populationmentioning

confidence: 79%

“…A systematic analysis of HF cost-of-illness (COI) indicated that hospitalisation contributed 44-96% to the overall direct cost of HF ( 9 ). A registry-based COI study conducted in a hospital in East Malaysia found that the mean cost of HF per patient was about USD 6,017 and inpatient cost contributed to about 90% of the total cost ( 10 ). The reported cost from Malaysia was considerably lower than the cost reported in the USA and European countries ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study

Ong

Low²,

Yew³

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

BackgroundEstimation of the economic burden of heart failure (HF) through a complete evaluation is essential for improved treatment planning in the future. This estimation also helps in reimbursement decisions for newer HF treatments. This study aims to estimate the cost of HF treatment in Malaysia from the Ministry of Health’s perspective.Materials and methodsA prevalence-based, bottom-up cost analysis study was conducted in three tertiary hospitals in Malaysia. Chronic HF patients who received treatment between 1 January 2016 and 31 December 2018 were included in the study. The direct cost of HF was estimated from the patients’ healthcare resource utilisation throughout a one-year follow-up period extracted from patients’ medical records. The total costs consisted of outpatient, hospitalisation, medications, laboratory tests and procedure costs, categorised according to ejection fraction (EF) and the New York Heart Association (NYHA) functional classification.ResultsA total of 329 patients were included in the study. The mean ± standard deviation of total cost per HF patient per-year (PPPY) was USD 1,971 ± USD 1,255, of which inpatient cost accounted for 74.7% of the total cost. Medication costs (42.0%) and procedure cost (40.8%) contributed to the largest proportion of outpatient and inpatient costs. HF patients with preserved EF had the highest mean total cost of PPPY, at USD 2,410 ± USD 1,226. The mean cost PPPY of NYHA class II was USD 2,044 ± USD 1,528, the highest among all the functional classes. Patients with underlying coronary artery disease had the highest mean total cost, at USD 2,438 ± USD 1,456, compared to other comorbidities. HF patients receiving angiotensin-receptor neprilysin-inhibitor (ARNi) had significantly higher total cost of HF PPPY in comparison to patients without ARNi consumption (USD 2,439 vs. USD 1,933, p < 0.001). Hospitalisation, percutaneous coronary intervention, coronary angiogram, and comorbidities were the cost predictors of HF.ConclusionInpatient cost was the main driver of healthcare cost for HF. Efficient strategies for preventing HF-related hospitalisation and improving HF management may potentially reduce the healthcare cost for HF treatment in Malaysia.

show abstract

Section: Resource Utilisation By Healthcare Componentssupporting

confidence: 75%

Section: Resource Utilisation By Healthcare Componentssupporting

confidence: 73%

Section: Demographic Of Study Populationmentioning

confidence: 79%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study

Ong

Low²,

Yew³

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, HF is used to approximate the cost of cardiac complications. The cost of cardiac complications was extracted from a local HF registry-based analysis of a cost-of-illness study, which was USD 536.36 [ 31 ].…”

Section: Methodsmentioning

confidence: 99%

Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective

Shafie

Wong

Ibrahim

et al. 2021

Orphanet J Rare Dis

Self Cite

View full text Add to dashboard Cite

Background Transfusion-dependent thalassaemia (TDT) is a hereditary blood disorder in which blood transfusion is the mainstay treatment to prolong survival and improve quality of life. Patients with this disease require blood transfusion at more than 100 ml/kg annually and iron-chelating therapy (ICT) to prevent iron overload (IOL) complications. There are substantial numbers of TDT patients in Malaysia, but limited data are available regarding the economic burden associated with this disease. The purpose of this study was to determine the lifetime cost of TDT from a societal perspective and identify potential factors increasing patient and family expenditures among thalassaemia populations. Methods The total lifetime cost per TDT patient (TC1) is the sum of lifetime healthcare cost (TC2) and lifetime patient and family healthcare expenditure (TC3). TC2 was simulated using the Markov model, taking into account all costs subsidized by the government, and TC3 was estimated through a cross-sectional health survey approach. A survey was performed using a two-stage sampling method in 13 thalassaemia centres covering all regions in Malaysia. Results A TDT patient is expected to incur TC2 of USD 561,208. ICT was the main driver of cost and accounted for 56.9% of the total cost followed by blood transfusion cost at 13.1%. TC3 was estimated to be USD 45,458. Therefore, the estimated TC1 of a TDT patient was USD 606,665. Sensitivity analyses showed that if all patients were prescribed oral ICT deferasirox for their lifetime, the total healthcare cost would increase by approximately 65%. Frequency of visits to health facilities for blood transfusion/routine monitoring and patients who were prescribed desferrioxamine were observed to be factors affecting patient and family monthly expenses. Conclusion The lifetime cost per TDT patient was USD 606,665, and this result may be useful for national health allocation planning. An estimation of the economic burden will provide additional information to decision makers on implementing prevention interventions to reduce the number of new births and medical service reimbursement.

show abstract

Budget Impact Analysis of Dapagliflozin in Treating Patients With Heart Failure With Reduced Ejection Fraction From the Perspective of Malaysian Public Healthcare System

Tan,

Low,

Ong

2024

Clinical Therapeutics

View full text Add to dashboard Cite

Registry based analysis of cost-of-illness study among stage C heart failure patients at Hospital Queen Elizabeth II, Sabah, Malaysia

Cited by 7 publications

References 39 publications

Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study

Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study

Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective

Budget Impact Analysis of Dapagliflozin in Treating Patients With Heart Failure With Reduced Ejection Fraction From the Perspective of Malaysian Public Healthcare System

Contact Info

Product

Resources

About